-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Morgan Stanley Adjusts Price Target on Fate Therapeutics to $8 From $35, Maintains Equalweight Rating

Morgan Stanley Adjusts Price Target on Fate Therapeutics to $8 From $35, Maintains Equalweight Rating

MT Newswires · 01/06/2023 06:26